Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimer's Disease

Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in
                    People at Risk of Alzheimer's Disease

PR Newswire

BOSTON, Jan. 9, 2014

BOSTON, Jan. 9, 2014 /PRNewswire/ --Akili Interactive Labs Inc. ("Akili")
announced today that it has entered into an agreement with Pfizer Inc. to test
the ability of Akili's mobile video game platform ("Project EVO") to detect
cognitive differences in healthy elderly people at risk of developing
Alzheimer's disease. To Akili's knowledge this is the first time that a large
pharmaceutical company will test the use of a mobile video game as a clinical
tool to determine early signs of neurodegenerative disease pathology.

Under the agreement, Pfizer will conduct a clinical trial that will evaluate
healthy elderly subjects with and without the presence of amyloid in their
brains, as determined by Positron Emission Tomography (PET) imaging.
Approximately 100 individuals are expected to be enrolled with their cognitive
abilities assessed both at baseline, and over the course of one month of game
play. The goal of the trial is to investigate the Akili game as a biomarker or
clinical endpoint for potential use in future Alzheimer's trials.

The Akili video game platform is designed to quantify and improve the ability
of individuals to deal with cognitive interference (distractions and
interruptions), which impacts their ability to pay attention, plan and make
decisions. Such deficits are common symptoms of many degenerative diseases
like Alzheimer's, as well as psychiatric conditions such as ADHD, autism and
depression. The underlying Akili platform technology originated from the
laboratory of Adam Gazzaley, M.D., Ph.D. at the University of California, San
Francisco and was the cover story of the journal Nature in September 2013. Dr.
Gazzaley is a co-founder and Chief Science Advisor to Akili.

"It's great to have Pfizer as a partner in an area where there is a clear need
for novel approaches. Our collaboration with Pfizer is an example of Akili's
strategy of applying rigorous science and testing through clinical trials to
develop an entirely new class of medical products," said Eric Elenko, Akili's
Co-founder and Chief Business Officer.

"This partnership is another example of Pfizer's commitment to embracing
innovative technologies that have the potential to further research into
neuroscience diseases," said Michael Ehlers, Senior Vice President and Chief
Scientific Officer of the Neuroscience Research Unit at Pfizer. "A tool that
enables cognitive monitoring for the selection and assessment of clinical
trial patients has the potential to be an important advance in Alzheimer's
research and beyond."

In the last year, Akili has garnered approximately seven million dollars in
cash and non-dilutive funding equivalents, including this Pfizer collaboration
and a previously undisclosed investment from and collaboration with Shire
Pharmaceuticals (Nasdaq: SHPG). Akili is testing Project: EVO in several other
medical conditions where executive function is impaired including ADHD,
depression and autism.

About Akili Interactive Labs
Akili is combining cutting edge neuroscience and top-tier gaming to produce
first-in class therapeutic and monitoring tools that have the look and feel of
a video game. With a product that is both engaging and validated through
rigorous science, the company is seeking to produce highly effective
healthcare products. The company was founded by PureTech
(www.PureTechHealth.com) and Enlight (www.enlightbio.com) together with
leading neuroscientists and top tier game designers. For more information see
www.AkiliInteractive.com.

About Alzheimer's disease
Alzheimer's disease is the most common form of dementia, a general term for
memory loss and other intellectual abilities serious enough to interfere with
daily life. Nearly 5 million Americans are currently living with the disease.
Alzheimer's is the 6th leading cause of death in the United States, and was
estimated to cost the country's medical system $203 billion dollars last year
alone. There are currently limited approaches to detect Alzheimer's disease in
individuals before major symptoms
display.

University of California Disclaimer
The information stated above was prepared by Akili Interactive Labs, Inc. and
reflects solely the opinion of the corporation. Nothing in this statement
shall be construed to imply any support or endorsement of Akili, or any of its
products, by The Regents of the University of California, its officers, agents
and employees.

SOURCE Akili Interactive Labs Inc.

Website: http://www.AkiliInteractive.com
Contact: Eric Elenko, 617-456-4716, ee@puretechhealth.com
 
Press spacebar to pause and continue. Press esc to stop.